Fasting Upregulates PPARα Target Genes in Brain and Influences Pituitary Hormone Expression in a PPARα Dependent Manner by König, Bettina et al.
Hindawi Publishing Corporation
PPAR Research
Volume 2009, Article ID 801609, 9 pages
doi:10.1155/2009/801609
Research Article
Fasting UpregulatesPPARα TargetGenesinBrain andInﬂuences
Pituitary Hormone Expression in a PPARα Dependent Manner
BettinaK¨ onig,1 ChristineRauer,1 SusannRosenbaum,1 CorinnaBrandsch,1
Klaus Eder,2 andGabrieleI.Stangl1
1Institute of Agricultural and Nutritional Sciences, Martin-Luther-University Halle-Wittenberg,
Halle (Saale), Germany
2Chair of Animal Nutrition, Center of Life and Food Sciences Weihenstephan, Technical University Munich,
Freising, Germany
Correspondence should be addressed to Bettina K¨ onig, bettina.koenig@landw.uni-halle.de
Received 17 July 2009; Accepted 29 August 2009
Recommended by Raghu Vemuganti
PPARα is a lipid-activable transcription factor that mediates the adaptive response to fasting. Recent data indicate an important
role of brain PPARα in physiological functions. However, it has not yet been shown whether PPARα in brain can be activated in the
fasting state. Here we demonstrate that fasting of rats increased mRNA concentrations of typical PPARα target genes implicated
in β-oxidation of fatty acids (acyl-CoA oxidase, carnitine palmitoyltransferase-1, medium chain acyl-CoA dehydrogenase) and
ketogenesis (mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase) in pituitary gland and partially also in frontal cortex and
diencephalon compared to nonfasted animals. These data strongly indicate that fasting activates PPARα in brain and pituitary
gland. Furthermore, pituitary prolactin and luteinizing hormone-β mRNA concentrations were increased upon fasting in wild-
type mice but not in mice lacking PPARα. For proopiomelanocortin and thyrotropin-β, genotype-speciﬁc diﬀerences in pituitary
mRNA concentrations were observed. Thus, PPARα seems to be involved in transcriptional regulation of pituitary hormones.
Copyright © 2009 Bettina K¨ onig et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The ability of animals to survive during food deprivation
requires biochemical and physiological responses to the lack
of food. The overall metabolic response to fasting operates
at numerous levels, and peroxisome proliferator-activated
receptor (PPAR)-α which belongs to the family of nuclear
hormone receptors mediates an adaptive response to fasting.
PPARα is directly activated by nonesteriﬁed fatty acids
(NEFAs) [1, 2] which are liberated from adipose tissue into
plasma by lipolytic stimuli and acts as a nutritional state
sensor by stimulating the transcription of genes involved
in fatty acid uptake through membranes, fatty acid binding
in cells, peroxisomal and mitochondrial fatty acid oxida-
tion, ketone body synthesis as well as glycogenolysis and
gluconeogenesis [3]. All of these metabolic responses are
crucial to shift the body fuel utilization from carbohydrates
and fat in the fed state to almost exclusively fat and ketone
bodies during fasting and to maintain blood glucose levels
to provide tissues such as brain with suﬃcient amounts of
glucose.
PPARα is expressed mostly in tissues with high rates
of fatty acid oxidation and peroxisomal metabolism like
brown adipose tissue, liver, kidney, and heart [3]b u ti s
also expressed in diﬀerent regions of the brain [4]. Several
studies exist that indicate an important role of brain PPARα
in physiological functions like neuroprotection [5] and the
control of whole-body glucose homeostasis during fasting
[6]. Furthermore, speciﬁc upregulation of the prolactin gene
in a pituitary cell line by PPARα was shown [7] indicating
a possible role of PPARα in transcriptional regulation of
pituitary hormone production.
Until now it is not known whether PPARα in brain
is indeed activated during fasting. It was shown that
administration of the PPARα agonist ciproﬁbrate upregu-
lates typical PPARα target genes such as mitochondrial 3-
hydroxy-3-methylglutaryl-(mHMG)-CoA synthase and, to
a lesser extent, acyl-CoA oxidase (ACO) and medium2 PPAR Research
chain acyl-CoA dehydrogenase (MCAD; [8]) and increases
the rate of fatty acid oxidation in brain homogenates
[9].
Thus, this study was designed to test whether fasting
would result in an activation of PPARα in brain of rats.
PPARα activation was measured by determination of mRNA
concentrations of the typical PPARα target genes such
as ACO, carnitine palmitoyltransferase (CPT)-1, medium
chain acyl-CoA dehydrogenase (MCAD), and mHMG-CoA
synthase.Acloﬁbrate-treatedgroupwasincludedtocompare
the eﬀects of fasting with those of PPARα activation by
a synthetic ligand. For analysis, we choose frontal cortex,
part of the diencephalon, and the pituitary gland which
are known to express PPARα in detectable amounts [4].
We could show a signiﬁcant upregulation of PPARα target
genes particularly in pituitary gland of rats. Considering
that and the described regulation of prolactin gene by
PPARα in a pituitary cell line [7], we analysed a possible
role of brain PPARα in regulation of pituitary hormones
during fasting. For that, we analysed mRNA concentrations
of prolactin, proopiomelanocortin (POMC), luteinizing
hormone (LH)-β, follicle-stimulating hormone (FSH)-β,
growthhormone(GH)andthyrotropin(TSH)-β inpituitary
g l a n do ff a s t e da n df e dP P A R α knockout and correspond-
ing wild-type mice. Obtained data indicate an involve-
ment of PPARα in transcriptional regulation of pituitary
hormones.
2.MaterialsandMethods
2.1. Animal Experiments. Animals were kept individually
in Macrolon cages in a room controlled for temperature
(22 ± 2◦C), relative humidity (50–60%), and light (12hours
light/dark cycle). All experimental procedures described
followed established guidelines for the care and handling
of laboratory animals and were approved by the council of
Saxony-Anhalt. Male Sprague-Dawley rats, with an average
initial body weight of 258g (±17; SD), were randomly
assigned to three groups (n = 9). All rats were fed a
commercial standard basal diet (“altromin 1324,” Altromin
GmbH, Lage, Germany). To standardize food intake, the
diets were fed daily in restricted amounts of 22g per
day. Water was available ad libitum from nipple drinkers
during the whole experiment. The animals were treated with
250mg/kg of cloﬁbrate in 1mL sunﬂower oil (cloﬁbrate
group) or with an equal volume of the vehicle sunﬂower
oil (control group and fasting group) by gavage once a day
2hours after beginning of the light cycle. Animals of the
fasting group were fasted 36hours before killing. During
food deprivation, they obtained water instead of sunﬂower
oil by gavage. At day 4 of treatment, animals received the last
dose of cloﬁbrate, sunﬂower oil, and water, respectively, and
7g of the diet (except fasting group) and were killed 4hours
later by decapitation under light anaesthesia with diethyl
ether. Blood was collected into heparinized polyethylene
tubes. The brains were removed and dissected. For analysis,
the pituitary gland, frontal cortex, and the ventral part of
diencephalon were used. The liver was excised. Brain and
liver samples for RNA isolation were snap-frozen in liquid
nitrogen and stored at −80
◦C.
Female PPARα knockout mice (129S4/SvJae-
Pparatm1Gonz/J) and corresponding wild-type control mice
(129S1/SvImJ) were purchased from the Jackson Laboratory
(Bar Harbor, USA). Mice from both genotypes with
an average initial body weight of 27.4g (±1.4; SD) were
randomly assigned to twogroups. Mice of the control groups
(wild-type mice n = 10 and PPARα knockout mice n = 10)
were fed ad libitum with a commercial standard basal diet
(altromin 1324). Mice of the fasting groups (wild-type mice
n = 10 and PPARα knockout mice n = 10) were fasted
48hours before killing. Mice were killed by decapitation
under light anaesthesia with diethyl ether. For RNA analysis,
the liver and pituitary gland were excised, snap-frozen in
liquid nitrogen, and stored at −80
◦C.
2.2. RT-PCR Analysis. Total RNA isolation from tissues and
cDNA synthesis were carried out as described [10]. For
RNA isolation from pituitary glands of mice, tissue samples
of two animals were pooled. The mRNA expression of
genes was measured by real-time detection PCR using SYBR
Green I and the Rotor Gene 2000 system (Corbett Research,
Mortlake, Australia) as described in [11]. Annealing tem-
perature for all primer pairs (Operon Biotechnologies,
Cologne, Germany; Table 1)w a s6 0
◦C (exception: mouse
mHMG-CoA synthase, TSHβ,5 8
◦C; mouse β-actin, 66
◦C).
For determination of mRNA concentration a threshold
cycle (Ct) and ampliﬁcation eﬃciency were obtained from
each ampliﬁcation curve using the software Rotor Gene
4.6 (Corbett Research). Calculation of the relative mRNA
concentration was made using the ampliﬁcation eﬃciencies
and the Ct values [12]. The housekeeping gene β-actin was
used for normalization.
2.3. Concentration of NEFA. The concentration of NEFA
in plasma was determined using an enzymatic reagent kit
(Wako Chemicals GmbH, Neuss, Germany).
2.4. Statistics. Data of all experiments were analyzed using
the Minitab Statistical Software (Minitab, State College, PA,
USA). Treatment eﬀects of rat experiment were evaluated by
one-wayANOVA.ForsigniﬁcantFvalues(P<. 05),meansof
the treatments (fasting, cloﬁbrate) were compared pairwise
with the control group by Student’s t-test. Treatment eﬀects
of mice experiment were analyzed by two-way ANOVA with
classiﬁcation factors being treatment (fasting), genotype and
the interaction of treatment (fasting) and genotype. In all
experiments, means were considered signiﬁcantly diﬀerent
for P<. 05.
3. Results
3.1. Final Body Weights of Rats and Mice. Final body weight
of rats was signiﬁcantly inﬂuenced by fasting but not by
cloﬁbrate treatment (control: 265 ± 18g; fasting: 241 ±
12g; cloﬁbrate treatment: 266 ± 17g; mean ± SD, n = 9).
Final body weights of fasted rats were lower than thosePPAR Research 3
Table 1: Characteristics of the speciﬁc primers used for RT-PCR analysis.
Gene Forward primer (5
  to 3
 ) Reverse primer (5
  to 3
 ) PCR product
size (bp)
NCBI
GenBank
β-Actin (rat) ATCGTGCGTGACATTAAAGAGAAG GGACAGTGAGGCCAGGATAGAG 429 BC063166
ACO (rat) CTTTCTTGCTTGCCTTCCTTCTCC GCCGTTTCACCGCCTCGTA 415 NM017340
CPT1A (rat) GGAGACAGACACCATCCAACATA AGGTGATGGACTTGTCAAACC 416 NM031559
CPT1C (rat) CATCTCCAGCAAGCAATCAA GATCCCCAATACCCCTGTCT 299 BC105882
LCAD (rat) AAGGATTTATTAAGGGCAAGAAGC GGAAGCGGAGGCGGAGTC 380 NM012849
MCAD (rat) CAAGAGAGCCTGGGAACTTG CCCCAAAGAATTTGCTTCAA 154 NM016986
Mitochondrial
HMG-CoA synthase
(rat)
GGCCTTGGACCGATGCTATGC GGGAGGCCTTGGTTTTCTTGTTG 323 BC083543
PPARα (rat) CCCTCTCTCCAGCTTCCAGCCC CCACAAGCGTCTTCTCAGCCATG 555 NM013196
β-Actin (mouse) ACGGCCAGGTCATCACTATTG CACAGGATTCCATACCCAAGAAG 87 NM007393
ACO (mouse) CAGGAAGAGCAAGGAAGTGG CCTTTCTGGCTGATCCCATA 189 NM015729
LHβ (mouse) GTCCCAGGACTCAACCAATG GGGAGGGAGGGATGATTAGA 110 NM008497
Mitochondrial
HMG-CoA synthase
(mouse)
CCTCTGTGAATCCTGGGTGT CTGTGGGGAAAGATCTGCAT 141 NM008256
POMC (mouse) GGGTCCCTCCAATCTTGTTT GCACCAGCTCCACACATCTA 137 NM008895
Prolactin (mouse) CTCAGGCCATCTTGGAGAAG TCGGAGAGAAGTCTGGCAGT 174 NM011164
FSHβ (mouse) AGGGAGGAAAGGAAAGTGGA AGCCAGCTTCATCAGCATTT 202 NM008045
GH (mouse) ACGCGCTGCTCAAAAACTAT GCTAGAAGGCACAGCTGCTT 120 NM008117
TSHβ (mouse) TCAACACCACCATCTGTGCT TCTGACAGCCTCGTGTATGC 239 NM009432
of nonfasted (control) rats (P<. 05). Final body weights
of mice were signiﬁcantly inﬂuenced by fasting and the
genotype (wild-type control, 26.4 ± 1.4g; wild-type fasting,
23.5 ± 1.5g; PPARα-knockout control, 27.8 ± 1.4g; PPARα-
knockout fasting, 24.4 ± 1.4g; mean ± SD; n = 10). Final
body weights of fasted mice were lower than those of non-
fastedmice(P<. 05);ﬁnalbodyweightsofPPARα-knockout
mice were higher than those of wild-type mice (P<. 05).
Theinteractionoffastingandgenotypehadnoeﬀectonﬁnal
body weights.
3.2. Concentrations of NEFA in Plasma of Rats. Fasted rats
had higher concentrations of NEFA in plasma than control
rats whereas those of cloﬁbrate treated rats were unchanged
(control: 234 ± 37μmol/L; fasted: 676 ± 162; cloﬁbrate: 216
± 32μmol/L; n = 9f o re a c hg r o u p ;P<. 05).
3.3. mRNA Concentrations in Rat Brain and Pituitary Gland.
To elucidate a possible activation of PPARα in rat brain
by fasting, we measured mRNA concentrations of typical
PPARα target genes in frontal cortex, diencephalon, and
pituitary gland of fasted and non-fasted rats. mRNA con-
centration of ACO was higher in pituitary gland of fasted
rats compared to control rats (P<. 05; see Figure 1). Oral
treatment of a third group of rats with the synthetic PPARα
agonist cloﬁbrate did not change mRNA concentration
of ACO in all brain areas examined and pituitary gland
compared to control rats (Figure 1).
Concentration of CPT1A mRNA, which represents the
widely expressed liver isoform of CPT1 [13], was higher
in pituitary gland of fasted rats compared to control rats
(P<. 05; see Figure 1). In cloﬁbrate treated rats, CPT1A
mRNA concentration was higher in frontal cortex compared
to control rats (P<. 05; Figure 1). mRNA concentration of
CPT1C, the brain speciﬁc isoform of CPT1 [14], was higher
inpituitaryglandoffastedratscomparedtocontrolrats(P<
.05; Figure 1). Cloﬁbrate treatment did not change mRNA
concentration of CPT1C in all brain areas examined and
pituitary gland compared to control rats (Figure 1). MCAD
mRNA concentration was higher in pituitary gland of fasted
rats compared to control rats (P<. 05; Figure 1). Cloﬁbrate
treatment did not change mRNA concentration of MCAD
in all examined tissues (Figure 1). In fasted and cloﬁbrate
treated rats, mRNA concentrations of LCAD were higher in
frontal cortex and pituitary gland than those in control rats
(P<. 05; Figure 1).
mHMG-CoA synthase mRNA concentration was higher
in frontal cortex, diencephalon, and pituitary gland of fasted
and cloﬁbrate treated compared to control rats (P<. 05;
Figure 1).
Fasting tended to increase the mRNA concentration of
PPARα in pituitary gland compared to nonfasting (P =
.073; Figure 1). Cloﬁbrate treatment did not alter mRNA
concentration of PPARα in all brain areas examined and
pituitary gland compared to control rats (Figure 1).
3.4. mRNA Concentrations in Rat Liver. In liver, mRNA
concentrations of ACO, CPT1A, LCAD, and PPARα were
higher in fasted than in control rats (P<. 05; Figure 2).
In the liver of cloﬁbrate treated rats, mRNA concentrations4 PPAR Research
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Figure 1: Eﬀect of fasting or cloﬁbrate treatment on mRNA concentration of acyl-CoA oxidase (ACO), carnitine palmitoyltransferases
(CPT)-1A and -1C, medium chain acyl-CoA dehydrogenase (MCAD), long chain acyl-CoA dehydrogenase (LCAD), mitochondrial 3-
hydroxy-3-methylglutaryl-(mHMG)-CoA synthase, and peroxisome proliferator-activated receptor (PPAR)-α in diﬀerent brain areas of
rats. All rats obtained a standard basal diet for 4 days. Animals of the fasting group were fasted 36hours before killing. Rats of the cloﬁbrate
group were treated orally with 250mg/kg of cloﬁbrate per day. Values are means ± SD (n = 9). Symbols indicate signiﬁcant diﬀerence from
control rats (
∗P <. 05,
∗∗P <. 001).PPAR Research 5
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Figure 2: Eﬀect of fasting or cloﬁbrate treatment on mRNA
concentration of acyl-CoA oxidase (ACO), carnitine palmitoyl-
transferases (CPT)-1A, medium chain acyl-CoA dehydrogenase
(MCAD), long chain acyl-CoA dehydrogenase (LCAD), mitochon-
drial 3-hydroxy-3-methylglutaryl-(mHMG)-CoA synthase, and
peroxisome proliferator-activated receptor (PPAR)-α in the liver of
rats. All rats obtained a standard basal diet for 4 days. Animals of
the fasting group were fasted 36hours before killing. Rats of the
cloﬁbrate group were treated orally with 250mg/kg of cloﬁbrate per
day. Values are means ± SD (n = 9). Symbols indicate signiﬁcant
diﬀerence from control rats (
∗P <. 05,
∗∗P <. 001).
of ACO, CPT1A, MCAD, LCAD and mHMG-CoA synthase
were higher than in control rats (P<. 05; Figure 2).
3.5. mRNA Concentrations in Pituitary Gland of PPARα
Knockout and Wild-Type Mice. To elucidate a possible role
of PPARα in expression of pituitary hormones, wild-type
and PPARα knockout mice were fasted for 48hours. In
pituitary gland, the PPARα target gene ACO was not
signiﬁcantly increased in fasted mice compared to non-
fasted mice of both genotypes (Figure 3). Fasting led to an
increase of mHMG-CoA synthase mRNA concentration in
pituitary gland of wild-type mice (P<. 05; see Figure 3).
Fasting did also increase mHMG-CoA synthase mRNA in
PPARα knockout mice but this eﬀect was less than that
observed in wild-type mice (P<. 05; Figure 3). For pituitary
mHMG-CoA synthase, there was a tendency to interaction
of genotype and fasting (P = .090). For comparison, mRNA
levelsofACOandmHMG-CoAsynthasewerealsomeasured
in liver of mice. Liver ACO mRNA concentration was lower
in PPARαknockout than in wild-type mice (P<. 05) but was
not increased upon fasting for 48hours in both genotypes
(Figure 3). Liver mHMG-CoA synthase was increased upon
fasting in wild-type mice but not in PPARα knockout mice
and was lower in PPARα knockout mice than in wild-
type mice (P<. 05; see Figure 3). There was a signiﬁcant
interaction of genotype and fasting for liver mHMG-CoA
synthase mRNA (P<. 05).
Next we analysed mRNA concentrations of prolactin,
POMC, LHβ,F S H β,G H ,a n dT S H β in pituitary gland of
fasted and non-fasted wild-type and PPARα knockout mice.
mRNA concentration of prolactin in pituitary gland was
higher in fasted than in non-fasted wild-type mice (P<
.05; see Figure 4). In PPARα knockout mice, fasting caused
a decrease of prolactin mRNA concentration (P<. 05;
see Figure 4). Prolactin mRNA concentration of wild-type
and PPARα knockout control (fed) mice did not diﬀer. For
prolactin mRNA concentration in pituitary gland, there was
an interaction of genotype and fasting (P<. 05).
mRNA concentration of POMC in pituitary gland was
higher in fasted than in non-fasted mice of both genotypes
(P<. 05; see Figure 4). POMC mRNA concentration was
higher in fasted PPARα knockout mice than in fasted wild-
type mice (P<. 05; see Figure 4). There was no diﬀerence
in POMC mRNA levels between non-fasted groups of both
genotypes.
Fasting led to an increase of mRNA concentration of
LHβ in pituitary gland of wild-type (P<. 05) mice but
not of PPARα knockout mice (Figure 4). For LHβ mRNA
concentration, there was a tendency to interaction of geno-
type and fasting (P = .053). FSHβ mRNA concentration
in pituitary gland was higher in fasted than in non-fasted
mice of both genotypes (P<. 05; see Figure 4). For
GH mRNA concentration, no signiﬁcant diﬀerences were
observed between all four groups of mice (Figure 4).
Fasting led to a signiﬁcant decrease of TSHβ mRNA in
pituitary gland of both wild-type and PPARα knockout mice
(P<. 05; Figure 4). Furthermore, TSHβ mRNA level was
lower in PPARα knockout mice than in the corresponding
g r o u po fw i l d - t y p em i c e( P<. 05; see Figure 4).
4. Discussion
This study was designed to investigate the eﬀect of fasting
on the expression of PPARα target genes in rat brain. As
expected, food deprivation for 36hours led to a consid-
erable loss of body weight of the rats. Mobilization of
triacylglycerols from adipose tissue by fasting moreover
caused an increase in the concentrations of NEFA in plasma
whereas cloﬁbrate treatment did not change plasma NEFA
concentrations of the rats.
In this study, we could demonstrate for the ﬁrst time that
fasting of rats for 36hours upregulates mRNA concentration
of ACO, CPT1, MCAD, LCAD, and mHMG-CoA synthase
in pituitary gland and, partially, also in frontal cortex and
diencephalon of the brain. All enzymes are typical PPARα
target genes or PPARα responsive genes (LCAD; reviewed in
[3]), and the observed upregulation of these genes during
fasting strongly indicates PPARα activation in brain during
food deprivation. This ﬁnding supports the hypothesis of
Knauf et al. [6] that PPARα activation in brain is vital during
fasting.
It has been shown that PPARα is well expressed in
various brain areas and that it is colocalized with ACO
indicatingthatalsoinbraintissueperoxisomalβ-oxidationis
regulated by PPARα [4, 15]. Although it is generally thought
that the liver supplies the brain with ketone bodies as a
glucose-replacing fuel, for example, during fasting, it has
been demonstrated that fatty acids are oxidized by the brain
and isolated astrocytes [9, 16] and that cultured astrocytes
are able to synthesize ketone bodies from fatty acids [16]
assuming that astrocytes may provide neurons with ketone6 PPAR Research
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Figure 3: Eﬀect of fasting on mRNA concentrations of acyl-CoA oxidase (ACO) and mitochondrial 3-hydroxy-3-methylglutaryl-(mHMG)-
CoAsynthaseinpituitaryglandandliverofwild-type(+/+)andPPARαknockoutmice(−/−).Miceofbothgenotypeswere eitherfastedfor
48hours (control group) or fed a standard rodent diet ad libitum for 48hours (fed group). Livers and pituitary glands of mice were excised,
pituitary glands from two animals were pooled, total RNA was extracted, and mRNA abundances were determined by real-time detection
RT-PCR analysis using β-actin for normalization. Bars represent means ± SD (liver: n = 10; pituitary: n = 5). Means without a common
letter diﬀer, P<. 05. Signiﬁcant eﬀects (P<. 05) from two-way ANOVA: mHMG-CoA synthase (pituitary): genotype, fasting, fasting ×
genotype (P = .09); ACO (liver): genotype; mHMG-CoA synthase (liver): fasting, genotype, fasting × genotype.
bodies as a glucose-replacing fuel in vivo. This hypothesis is
supported by our ﬁndings that genes involved in β-oxidation
offattyacids(ACO,CPT1,MCAD,LCAD)andmHMG-CoA
synthase which is implicated in ketogenesis are upregulated
upon fasting in rat brain and pituitary gland.
Among the PPARα target genes analysed in brain,
mHMG-CoA synthase was upregulated strongest by fasting.
Regarding the diﬀerent brain areas tested, upregulation of
PPARα responsive genes in general was stronger in pituitary
gland than in frontal cortex and diencephalon. mHMG-
CoA synthase and LCAD were the only PPARα responsive
genes that were considerably upregulated by cloﬁbrate
treatmentin brain, withthe strongesteﬀectsin frontal cortex
followed by pituitary gland and diencephalon. These distinct
relative intensities of upregulation in the three brain areas
observed by fasting and cloﬁbrate treatment indicate that
the diﬀerent responses in frontal cortex, diencephalons, and
pituitaryglanduponfastingareprobablynotduetodiﬀerent
expression levels of PPARα.
In general, the eﬀect of fasting on PPARα responsive
genes in brain was much stronger than that of cloﬁbrate
treatment. In contrast, in the liver, upregulation of most of
these genes was much stronger in cloﬁbrate treated than in
fasted rats. This discrepancy may reﬂect the diﬀerent access
of PPARα agonists to the brain. It has been demonstrated
that ﬁbrates can access the brain but that they cross the
blood-brain barrier slowly [9, 17]. During fasting, hydrolysis
of triacylglycerols in adipose tissue is stimulated leading
to increased concentrations of plasma NEFA which then
activate PPARα in the liver. We suggest that the observed
activation of PPARα in brain by fasting was accomplished
by the strong increase in NEFA concentration in plasma
of fasted rats. It has been demonstrated that the access of
circulating NEFA to the central nervous system is generally
proportional to their plasma concentration [18]. Thus,
although both, cloﬁbrate, and NEFA are potent PPARα
agonists [19], the PPARα activation by NEFA released upon
fasting is stronger than that of orally administered cloﬁbrate.
NEFA that are released upon fasting also upregulate
PPARα transcription in the liver [20], as could be also
observed in rats fasted for 36hours in this study. In brain,
PPARα was slightly but not signiﬁcantly (P = .073) up-
regulated only in pituitary gland which corresponds well
with the upregulation pattern of its target genes which was
also the strongest in this area. Cloﬁbrate treatment of rats
did not change mRNA concentration of PPARα which is in
agreement with other studies showing that PPARα activation
by ﬁbrates does not necessarily upregulate expression of
PPARα [21, 22].
In the liver of rats, there was weak or even no upregula-
tionofPPARαresponsivegenesafter36hoursoffasting.This
isconsistentwithdatashowingthatmRNAconcentrationsofPPAR Research 7
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Figure 4: Eﬀect of fasting on mRNA concentrations of prolactin, proopiomelanocortin (POMC), luteinizing hormone (LH)-β, follicle-
stimulatinghormone(FSH)-β,growthhormone(GH),andthyrotropin(TSH)-β inpituitaryglandofwild-type(+/+)andPPARαknockout
mice (−/−). Mice of both genotypes were either fasted for 48hours (control group) or fed a standard rodent diet ad libitum for 48hours
(control group). Pituitary glands of mice were excised, pooled from two animals, total RNA was extracted, and mRNA abundances were
determined by real-time detection RT-PCR analysis using β-actin for normalization. Bars represent means ± SD (n = 5). Means without a
common letter diﬀer, P<. 05. Signiﬁcant eﬀects (P<. 05) from two-way ANOVA: prolactin: genotype, fasting × genotype; POMC: fasting,
genotype; LHβ: fasting, fasting × genotype (P = .053); FSHβ: fasting; TSHβ: fasting, genotype.
PPARα target genes in the liver of rats are upregulated after
24hours of fasting, but decrease after longer fasting times to
control levels [23]. In a preliminary experiment, we analysed
expression of PPARα target genes in brain of rats fasted for
24hours. Interestingly, upregulation of PPARα target genes
in brain after 24hours of fasting was much weaker than
after 36hours of fasting (data not shown) indicating that
activation of PPARα in brain is delayed compared to that in
liver. Further experiments regarding this time dependency of
PPARαactivationinbrainandlivermaybehelpfultoexplain
this phenomenon.
As already mentioned, the prolactin gene is activated
by PPARα as demonstrated in a rat pituitary tumor cell
line and in reporter gene assays [7]. Thus, our results
with fasted rats prompted us to investigate whether PPARα
activation upon fasting is involved in regulation of hormone
production in pituitary gland. Fasting led to an upregulation
of mHMG-CoA synthase in pituitary gland of wild-type
mice indicating PPARα activation. However, also in PPARα
knockout mice mRNA concentration of mHMG-CoA syn-
thase was increased upon fasting but not as strong as in wild-
type mice. In contrast, the upregulation of mHMG-CoA
synthase in livers of wild-type mice upon fasting could not
be observed in the livers of PPARα knockout mice indicating
the PPARα-dependent regulation of mHMG-CoA synthase
in liver. Thus, additional mechanisms seem to be involved
in upregulation of mHMG-CoA synthase mRNA in pituitary
gland upon fasting. It has been shown that in skeletal muscle
PPARβ/δ can compensate the lack of PPARα in regulation of
fattyacidhomeostasisduringstarvation[24].SincePPARβ/δ8 PPAR Research
is also ubiquitously expressed in brain [4] it is possible
that it can compensate at least in part the lack of PPARα
mediated upregulation of mHMG-CoA synthase in brain
of PPARα knockout mice upon fasting. The fact that no
upregulation of ACO was observed in liver and pituitary
gland of mice fasted for 48hours is consistent with the
marginalupregulationofACOobservedinratsafter36hours
of fasting and is attributed to the increased fasting time
[23].
Analysis of mRNA concentrations of several genes of
pituitary hormones in wild-type and PPARα knockout mice
revealed that prolactin gene mRNA was upregulated 1.3-
fold in wild-type mice upon fasting but was downregulated
about 50% in fasted PPARα knockout mice. Thus, our data
demonstrate for the ﬁrst time that the prolactin gene is
transcriptionallyregulatedbyPPARαinvivoandsupportthe
ﬁndings of Tolon et al. [7]. They demonstrated that the rat
prolactin promoter is stimulated by PPARα by a mechanism
diﬀerent from that commonly described for PPARα target
genesinvolving interactionofthePPARα/RXRαheterodimer
complex with a PPRE [7].
Besides prolactin, also for the LHβ mRNA a genotype-
dependentresponsetofastingwasobserved.The1.5-foldup-
reguation of LHβ mRNA concentration by fasting in wild-
type mice was not observed in PPARα knockout mice (P
value for interaction of treatment (fasting) and genotype:
.053). This indicates that PPARα may also be involved in
regulation of LHβ expression in pituitary gland during
fasting. Fasting also led to about 1.4-fold increases in
pituitaryFSHβmRNAconcentration;howeverthiseﬀectwas
observed both in wild-type and in PPARα knockout mice
indicating that PPARα is not involved in regulation of FSHβ
mRNA during fasting in mice.
POMC mRNA concentration was higher in pituitary
gland of PPARα knockout than of wild-type mice and it
was induced in both genotypes upon fasting. POMC, a
multifunctional precursor protein of a number of bioactive
peptides, is produced both in pituitary gland and hypotha-
lamus. Interestingly, recently it was described that in the
fed state hypothalamic POMC mRNA concentration is also
higher in PPARα knockout than in wild-type mice; however
it was downregulated upon 24hours of fasting in both
genotypes [6]. This diﬀerent behaviour of POMC mRNA
upon fasting may result from the fact that POMC expression
in hypothalamus and pituitary is controlled by independent
sets of enhancers [25].
During fasting, mRNA concentration of TSHβ was
reduced in pituitary gland of both wild-type and PPARα
knockout mice. Downregulation of TSHβ is part of a series
of changes in the hypothalamic-pituitary-thyroid axis [26].
Interestingly, TSHβ mRNA concentration was lower in mice
lacking PPARα than in wild-type mice indicating a role for
PPARα in regulation of TSHβ that should be analysed in
future studies.
5. Conclusions
In conclusion, the data of the present study show for the
ﬁrsttimethatfastingofratsupregulatestypicalPPARαtarget
genes in frontal cortex, diencephalon, and pituitary gland.
This strongly indicates that free fatty acids released upon
energy restriction from adipose tissue activate PPARα not
only in liver but also in brain. Besides a possible role of brain
PPARα in regulation of ketone body synthesis it seems to be
also involved in control of pituitary hormone production.
Thus, regarding the multitude of genes regulated by PPARα,
not only PPARα activation in liver, but also activation of
PPARα in brain seems to be an important step in adoption
to fasting.
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